FDA Commissioner Marty Makary Removed After Pressure Over Vape Approvals
Similar Articles
FDA Commissioner Marty Makary Resigns After 13-Month Tenor
FDA Commissioner's Status Unclear Amid Reported Push for Removal
FDA Acting Drug Center Director Tracy Beth Hoeg Removed
Trump Administration Appeals Injunction Against CDC Vaccine Policy Changes
HHS Confirms FDA Blocked Publication of Vaccine Studies
President Trump has approved the removal of Food and Drug Administration (FDA) Commissioner Marty Makary. The move follows reports that Trump scolded Makary for not moving quickly enough to approve flavored vape products, which the FDA subsequently authorized this week. The administration has not yet named an acting director to replace Makary.
Facts First
- President Trump has signed off on a plan to remove FDA Commissioner Marty Makary
- The removal followed pressure from Trump over the pace of approving flavored vape products
- The FDA authorized vapes from Glas on Tuesday after previously withholding approval due to youth enticement concerns
- The administration has not decided who will serve as acting director upon Makary's departure
- High-level leaders from the FDA, CDC, and NIH have left their positions during the Trump administration
What Happened
President Trump has approved a plan to remove FDA Commissioner Marty Makary. Reports indicate Trump scolded Makary over the weekend for not moving fast enough to approve flavored vape and nicotine products. Following this pressure, the FDA authorized vapes from the Los Angeles-based manufacturer Glas on Tuesday. Makary had previously avoided approving Glas's menthol, mango, and blueberry flavors due to concerns they could entice youth to vape.
Why this Matters to You
The FDA's oversight directly affects products you use, from medications and vaccines to tobacco and vaping products. A change in leadership could lead to shifts in how quickly new products, including controversial items like flavored vapes, are reviewed and approved. This may affect the availability and regulation of such products in the market. The agency has faced a range of complex issues, including vaccine approvals and abortion pill oversight, and leadership instability could influence how these matters are handled.
What's Next
The administration has not decided who will serve as acting FDA director upon Makary's departure. This leadership gap adds to existing vacancies at top health agencies; the CDC is currently without a director, and there is no surgeon general. The next commissioner will likely face continued pressure to balance product approval speed with public health safeguards, particularly on contentious issues like vaping.